News

ascopubs.org4d
Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.
Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone. Phase 1 study of ...
ascopubs.org4d
Circulating tumor cells and clinical outcomes in men with metastatic hormone sensitive prostate cancer treated with enzalutamide and docetaxel: Analysis of the ENZADA trial.
Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: A real-world clinical retrospective study.
BioSpace4d
ASCO 2025: XOFIGO® (radium-223 dichloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
At the primary analysis of the Phase 3 ERA-223 study that evaluated concurrent initiation of Xofigo in combination with abiraterone acetate plus prednisone/prednisolone in 806 asymptomatic or mildly ...